Top Story
Medical AffairsIn 2024, medical affairs teams are pivotal in driving strategic impact within the pharmaceutical industry. They navigate challenges in organizational transformation, artificial intelligence (AI) integration, and omnichannel engagement. Transforming organizational structures involves alignment with broader goals and excelling in scientific engagement. AI offers potential to streamline [...]
Latest Stories
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
The live session will focus on the latest salary and bonus trends for professionals in the field, including a comprehensive overview [...]
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
04/25/2024 04:46 PM ET
Processa Pharmaceuticals BCDA date announcement
BioCardia has an announcement scheduled for December 31, 2024 regarding their recent Phase 3 trial of CardiAMP (BCDA-02). The community is currently bullish on the prospects of progression, as the bulls outnumber bears by five [...]
Read More
04/25/2024 04:46 PM ET
Elicio Therapeutics ELTX date announcement
Now that the Phase 1/2 trial of ELI-002 - (AMPLIFY-7P) is completed, Elicio Therapeutics will announce their top-line results on June 30, 2024. Our predictive system gives the drug a 60.9% chance of making it [...]
Read More
04/25/2024 04:46 PM ET
Vistagen Therapeutics VTGN results announcement
Vistagen Therapeutics provided an update to their Phase 2a trial for PH15. Our analysts provided the following summary:
"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo [...]
04/25/2024 04:46 PM ET
BeiGene Ltd. BGNE date announcement
BeiGene Ltd. already had seven catalyst announcements coming up, but they added another one today. It will be announcing top-line results for their recent Phase 1a trial for BGB‑15025 monotherapy and in combination with tislelizumab [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest
